Glioma Therapy: Current Status and Future Prospects
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 31
Special Issue Editor
Interests: DNA damage and repair; DNA damage response; mutagenesis and carcinogenesis; cell death mechanisms; glioma therapy; alkylating agents; cellular senescence; senotherapeutics
Special Issue Information
Dear Colleagues,
The most severe forms of brain cancer are glioma grades 3 and 4 (glioblastoma). The treatment of these tumors remains a challenge. Although many new findings have been made regarding the molecular biology of these tumors, not much has changed in standard therapy. Radiation and chemotherapy with temozolomide and/or CCNU are still considered the gold standard. Immunotherapy and kinase inhibitors have not yet become established in glioma therapy, although several clinical trials are running. This Special Issue will discuss new anticancer drugs and therapeutic strategies, including biomedical supportive therapies with natural compounds targeting autophagy, cell death, and senescence pathways.
Dr. Bernd Kaina
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- temozolomide
- nitrosoureas
- immunotherapy
- biologicals
- tyrosine kinase inhibitors
- senotherapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
